The World Market for Vaccines, 2024

Vaccines offer long-term or permanent immunity against diseases. They have been a cornerstone of preventive medicine for over 70 years, stimulating an immune response to specific diseases. The widespread adoption of effective vaccines has led to the near-elimination of many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century.

Thanks to public vaccination programs, vaccine-preventable diseases and related deaths are now rare in developed nations and decreasing globally. Smallpox has been eradicated, polio eliminated in the Americas, and diseases like measles, rubella, tetanus, diphtheria, and Haemophilus influenzae type b controlled. Beyond preventing illness and death, vaccines also improve quality of life and productivity. They help prevent disease outbreaks and reduce healthcare costs, providing significant societal benefits.

Kalorama Information's latest report, The World Market for Vaccines, 2024, offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines. Since the early 2000s, Kalorama has consistently published new editions of The World Market for Vaccines every two years. The report includes market forecasts, company market share data, and expert market estimates for different vaccine categories.

The World Market for Vaccines, 2024 also examines market trends for human vaccines used to prevent various diseases. It specifically focuses on both commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Additionally, the report discusses selected emerging vaccines in development.

Vaccines covered in the report with sizing and market share include:

• Combinations (tetanus, pertussis, Hib, Hepatitis, polio)
• Hepatitis
• HPV
• Influenza
• Meningitis
• Pandemic vaccines/COVID-19
• Pneumococcal
• Rotavirus
• RSV
• Shingles
• Others (travel, endemic, etc.)

The report also examines key companies involved in the market. Companies profiled in the report include:

• AstraZeneca
• Bavarian Nordic, A/S
• Bharat Biotech International Ltd.
• Bio Farma
• BioNTech SE
• CSL Limited/Seqirus
• Dynavax Technologies
• Emergent BioSolutions, Inc.
• GlaxoSmithKline, Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson/Crucell/Janssen
• Merck & Co, Inc.
• Moderna, Inc
• Novavax, Inc.
• Pfizer, Inc.
• Sanofi Pasteur
• Serum Institute, Inc.
• Sinovac Biotech Ltd.
• Soligenix, Inc.
• Takeda Pharmaceutical Co, Ltd.
• Valneva SE

Scope and Methodology

The World Market for Vaccines, 2024 examines the market for human vaccines used to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines. It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period. This report does not include therapeutic vaccines such as allergy and cancer vaccines.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2023 year and forecasts are provided for 2028.  Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends and form the basis of the forecasting and competitive analysis.

It should also be noted that due to the very broad scope of this report, with the exception of healthcare spending forecasts, data provided is representative but is not intended to be exhaustive. This includes, for example, tables of vaccines in development and regional economic indicators, etc. Additionally, some statistics, such as those related to venture capital investment, are subject to wide divergences across different sources; where data could not be confidently obtained, trends were discussed rather than absolute numerical values.